This week FDA posted two warning letters to device manufacturers and two to drug manufacturers.

One of the drug manufacturers produces homeopathic drugs, which continues FDA’s focus on this area of the industry. The other drug manufacturer, located in India, was cited for failures to ensure the quality of recovered solvents. This is reminiscent of warning letters from last year that identified recovered solvents as being one of the potential sources of nitrosamine contamination in “sartan” drug products.

Drug Warning and Untitled Letters

Washington Homeopathic Products, Inc.

Washington Homeopathic Products, Inc. (Berkeley Springs, WV) received a warning letter on June 19, 2020, based on the outcome of an inspection ending July 2, 2019. In addition to adulteration, the FDA deemed that the firm is distributing unapproved new drugs. Consistent with recent warning letters to manufacturers of homeopathic drugs, FDA expressed concern because many of the products are labeled to contain potentially toxic ingredients. FDA says the firm’s Quality Systems are inadequate and recommends they hire qualified consultants to assist them in coming into compliance with regulations.

Deficiencies include but are not limited to:

  • The firm does not provide adequate Quality oversight for the drug products and components they receive, manufacture, or distribute. The firm admitted they failed to identify roles and responsibilities with their suppliers. The firm acquired a component/product that had been placed on Import Alert 66-40 and continued to distribute it.

  • Purchased raw materials were not testing for identity before release to manufacturing. The firm’s response was to perform a risk assessment to address this failure. FDA states “It is unclear in your response how your risk assessment would address drugs manufactured without appropriate raw material testing.”  

  • The firm did not adequately validate analytical methods for raw material testing and also for drug product testing

Vega Life Sciences Private Limited

Vega Life Sciences Private Limited (Telangana, India) received a warning letter on June 17, 2020, based on the outcome of an inspection ending November 28, 2019. The firm is a contract solvent recovery facility for API manufacture. It will be interesting to see if there is FDA follow up at the API sites which contract with this firm for solvent recovery. FDA suggests the firm hire a qualified consultant to assist them in coming into GMP compliance. Further, the firm was placed on import alert on April 14, 2020.

Deficiencies include but are not limited to:

  • Failure to establish and follow procedures to control impurity risks in solvent recovery. For example, the firm did not use standards in GC testing of solvents and they failed to establish an impurity profile for recovered solvents or investigate unknown peaks that were apparent in chromatograms. During the inspection, the firm provided investigators with a letter stating they had terminated processing recovered solvents for customers, but it is not clear that they would permanently cease this operation. 

  • The cleaning of shared equipment used in solvent recovery is inadequate.  Also, no records are available to document the cleaning of the non-dedicated equipment. The firm’s response was not adequate because it did not include a thorough evaluation that would ensure equipment was properly cleaned. 

  • Failure to exercise controls over computerized systems to ensure the integrity of the data generated by the firm including (but not limited to) missing raw data files, shared passwords and username, failure to back up data from stand-alone equipment, procedures governing audit trail management. 

Device Warning and Untitled Letters

Greiner Bio-One North America Inc

Greiner Bio-One North America Inc (Monroe, NC) received a warning letter on April 16, 2020, based on the outcome of an inspection ending December 13, 2019.  The firm manufactures Vacuette brand blood collection tubes. 

Deficiencies identified in the warning letter include but are not limited to:

  • The firm did not complete validation testing prior to the release of the product made to qualify a new supplier. The “draw volume” testing was not completed before the new material was released for use in manufacturing. 

  • The firm does not adequately manage complaints. Four device failures from June 2019 were not entered into the complaint system.

  • The molding machine used to manufacture the collection tubes was not validated. The warning letter identifies several shortcomings in the PQ activity.

  • Procedures for implementing CAPA activities are not adequate. For example, a CAPA to address validation of the manufacturing process and software validation did not include data required to demonstrate that requirements were met. 

  • The firm did not establish procedures to ensure that finished devices met requirements.

  • The calibration statuses of instruments used in manufacture were overdue for calibration. 

  • Quality Agreement did not specify responsibility for design validation.

  • Sampling plans are not statistically justified. 

  • The firms did not submit adequate MDRs, and thus products are deemed misbranded. 

Luminex Corporation

Luminex Corporation (Austin, Texas) received a warning letter on June 26, 2020, based on the outcome of an inspection ending February 14, 2020. The firm manufactures microsphere-based and PCR-based multiplexing systems for in-vitro diagnostic use or research use including software and hardware. Deficiencies include but are not limited to:

  • Failure to validate, review, and approve a manufacturing change for the calibration heater test fixtures.

  • The firm has not followed its own SOP regarding CAPA actions.  Impacted product was not immediately contained after problems were identified.

  • Calibration and verification results for device servicing have not been kept since 2016. 

  • Quality requirements that must be met by suppliers were not established or maintained. 

  • FDA also deemed the VERIGENE SP Processor is misbranded because the firm failed or refused to furnish material or information regarding the device.

Letters to Compounding Pharmacies and Outsourcing Facilities

No letters were issued this week. 

BIMO, GCP and GLP Warning and Untitled Letters

No letters were issued this week. 

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets
Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.